Here we show the ability of using Gadolinium (Gd) labeled thermosensitive liposomal nanoparticle (TSLnp) as a delivery system for anticancer drug, gemcitabine (Gem) to human pancreatic tumors. Pancreatic cancer (PCa) due to its high malignancy, poor prognosis and resistance to chemotherapy is one of the leading cancer-associated death in the United States. The proposed agent showed significant Gem accumulation in heated tumor relative to free Gem. Gd labeled TSLnp (Gd-TSLnp) show contrast in ex vivo tumor tissue. The Gd-TSLnp show increased T1 contrast in vivo with an implanted tumor compared to Gd and targets the tumor tissue.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords